.
Search
Dr. Neha Pagidipati and Dr. C. Michael Gibson discuss how the new lipid guidelines are moving the needle on LDL lowering: earlier, lower, longer.
The recent Vesalius trial adds to the data supporting lower is better, and suggests that even lower (an achieved LDL of 45 […]
Dr. Prem Soman and Dr. C. Michael Gibson Discuss: Long-Term Survival Benefits and Disease Stabilization With Acoramidis In Patients With Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Disclosures: Supported by an independent educational grant from BridgeBio Pharma Inc.